HealthQuill Sickle cell disease
Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a company statement.
Drugs Health Pharma

Pfizer pulls out sickle cell therapy from global markets, cites death, snags

Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a.

Read More
The receptor of Oxytocin, a hormone considered essential to forming social bonds, may not play the role that scientists have assigned it for the past 30 years, according to US scientists.
Drugs Health Medical

Opinion: Sickle Cell Disease and gene therapy

By K. Leelamoni December 19, 2023: Recent reports about the FDA’s approval of gene therapy to treat Sickle Cell Anemia mark a major.

Read More
The USFDA has approved two treatments for sickle cell disease, one of them the first in the US based on gene-editing technology.
Drugs Health Pharma

US drug regulator approves two treatments for sickle cell disease 

HQ Team December 8, 2023: The USFDA has approved two treatments for sickle cell disease, one of them the first in the US.

Read More
The receptor of Oxytocin, a hormone considered essential to forming social bonds, may not play the role that scientists have assigned it for the past 30 years, according to US scientists.
Drugs Health Medical Pharma

Gene therapy cure for sickle cell awaits advisory approval

HQ Team October 28, 2023: Advisers to the Food and Drug Administration (FDA) are set to review a gene therapy for sickle cell.

Read More
US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria.
Drugs Health Pharma

Gene editing kills female mosquitoes that spread malaria

HQ Team July 10, 2023: US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria..

Read More
gene editing
Drugs Health Medical Pharma

FDA considering approval for first ever CRISPR gene editing technology drug

HQ Team June 10, 2023:The Food and Drug Administration (FDA) has accepted an application for what could become the first-ever marketed medicine based.

Read More
US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda expires by the end of the decade.
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More